Pharmacokinetics and Safety of Erlotinib and its Metabolite OSI-420 in Infants and Children with Primary Brain Tumors

PURPOSE: Erlotinib (Tarceva®), a potent small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase, has been evaluated to treat infants and children with primary brain tumors. The pharmacokinetics of erlotinib and its primary metabolite OSI-420 were characterized and exposure-s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Chemother Pharmacol
Hauptverfasser: Reddick, Samuel J., Campagne, Olivia, Huang, Jie, Onar-Thomas, Arzu, Broniscer, Alberto, Gajjar, Amar, Stewart, Clinton F.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6773504/
https://ncbi.nlm.nih.gov/pubmed/31392390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03921-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge